Update on Janus kinase antagonists in inflammatory bowel disease.
Ontology highlight
ABSTRACT: Janus kinase (JAK) inhibitors have emerged as a novel orally administered small-molecule therapy for the treatment of ulcerative colitis and possibly Crohn disease. These molecules are designed to selectively target the activity of specific JAKs and to offer a targeted mechanism of action without risk of immunogenicity. Based on data from clinical trials in rheumatoid arthritis and phase 2 studies in inflammatory bowel disease, tofacitinib and other JAK inhibitors are likely to become a new form of medical therapy for the treatment of inflammatory bowel disease.
SUBMITTER: Boland BS
PROVIDER: S-EPMC4129380 | biostudies-literature | 2014 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA